In this article, we are going to take a look at where Moderna Inc. (NASDAQ ... saying that data on mRNA vaccines sent by the ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic began—proof that health authorities had planned the pandemic in advance.

Moderna (NASDAQ:MRNA) took a hit Tuesday as Barclays downgraded the stock from Overweight to Equal Weight, citing policy ...

Explore the evolution of vaccine technology from Jenner to mRNA, highlighting India's role in COVID-19 vaccine development.

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...

By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...